Asia Fresh News

Asia Fresh Stories

Mundipharma Launches Step-change Cancer Care Medicine Akynzeo(R) in Singapore

leave a comment »

— Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and troubling side effects of cancer chemotherapy
— Akynzeo® is the first and, for the time being, only long-lasting, dual action, single capsule for CINV prophylaxis

SINGAPORE /PRNewswire/ — Akynzeo® has been approved for use in Singapore to prevent CINV. Without appropriate antiemetic prophylaxis 70-80% of all cancer patients receiving chemotherapy experience nausea and/or vomiting.1

Akynzeo® is a combination of netupitant (highly-selective NK1 receptor antagonist) and palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) that is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat course of cancer chemotherapy, included, but not limited to, highly emetogenic chemotherapy.

Akynzeo® is the first and, for the time being, only available CINV prophylactic agent that targets two critical CINV pathways in one capsule that is effective up to five days.2, 3, 4 The current treatment involves multiple doses of multiple medicines that have to be administered over five days beginning at the start of every chemotherapy cycle.5, 6, 7

Studies have shown that the efficacy of Akynzeo® were better than current available anti-emetics and is maintained across multiple cycles of chemotherapy.2, 3, 4 99% of patients receiving highly emetogenic chemotherapy (risk >90% to cause CINV) reported no vomiting and no significant nausea on day one after chemotherapy and that figure remained as high as 90% for days two-five.3, 4

Mundipharma — which has been granted the exclusive rights to distribute Akynzeo® from Helsinn Healthcare S.A. — is well positioned to distribute the medicine in Singapore. Mundipharma has significant presence in the country and expertise in cancer supportive care, particularly CINV — Mundipharma also distributes the anti-CINV medicine Aloxi®, from Helsinn Healthcare SA, in Singapore.

Dr. Wong Seng Weng, Medical Director & Consultant Specialist in Medical Oncology, The Cancer Centre (TCC) in Singapore said, “At TCC our aim is to work closely with partners, who continue to break new grounds in the provision of healthcare services. Akynzeo® is one such drug which we believe will be of immense value to patients.”

Akynzeo® has been recommended by three international guidelines: the National Comprehensive Cancer Network, the American Society for Clinical Oncology and MASCC/ESMO (Multinational Association of Supportive Care in Cancer / European Society of Medical Oncology).8, 9, 10

Raman Singh, President, Mundipharma Asia Pacific, Latin America, the Middle East & Africa said: “CINV can be seriously debilitating, and the treatment complicated to adhere to, so we’re delighted to be introducing this new medicine for cancer sufferers in Singapore. It is another demonstration of our commitment to delivering innovative medicines to patients in Singapore and ultimately improving their quality of life.”


Feyer P, Jordan K. Ann Oncol 2011; 22(1): 30-38Gralla R et al. Ann Oncol. 2014; 25(7): 1333-1339
Hesketh PJ et al. Ann Oncol. 2014; 25(7): 1340-1346
Aapro et al., Ann Oncol 2014; 25: 1328-1333
Curran MP et al. Drugs. 2009;69(13):1853-78
Viale PH. Clin J Onc Nurs. 2005;9(1):77-84
Lorusso V. Ther Clin Risk Manag. 2016 Jun 7;12:917-25.
Basch E et al. J Clin Oncol. 2011 ; 29:4189-4198
Hesketh PJ, et al. J Clin Oncol 2016;34:381-6. Available at:

Click to access antiemesis.pdf

Roila F. et al. Ann Oncol. 2016 Sep;27(suppl 5):v119-v133; Available at:
About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit:

Logo –

Source: Mundipharma
Related Links:

Written by asiafreshnews

October 31, 2016 at 2:27 pm

Posted in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: